Abstract
Introduction
The pleiotropic effects of statins have attracted considerable attention in oncological treatment. Several preclinical and epidemiological studies have highlighted their potential anti-tumor properties in patients with colorectal cancer, although results have been conflicting. This study aimed to examine the association between statin exposure before colorectal cancer surgery with long and short-term survival outcomes.
Methods
This retrospective propensity score-adjusted study was conducted on a Danish cohort of patients who underwent elective curative-intended surgery for stage I–III colorectal cancer in 2008–2020, using four national patient databases. The primary and secondary outcomes were overall, 90-day, and disease-free survival. Propensity scores were calculated using all available data to match patients with and without statin exposure in a 1:1 ratio.
Results
Following propensity score matching, 7120 patients were included in the primary analysis. The median follow-up time was 5 years. A Cox proportional hazards model showed no statistically significant difference in overall survival between patients with or without statin exposure 365 days before surgery (HR 0.93, 95% CI 0.85–1.02) and no association with 90-day survival (OR 0.91, 95% CI 0.76–1.10). However, a subgroup analysis examining a 90-day exposure before surgery found a statistically significant association with increased overall survival (HR 0.85, 95% CI 0.77–0.93).
Conclusion
Although a subgroup of patients with a preoperative exposure time of 90 days showed statistically significant better overall survival, we found no statistically significant association between statin exposure 1 year before colorectal cancer surgery and overall survival.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Colorectal cancer (CRC) is the third most prevalent cancer worldwide and the second leading cause of cancer-related deaths [1]. Furthermore, the incidence of early-onset CRC is increasing. Thus, the growing number of patients diagnosed with CRC presents a considerable global health challenge [2]. Surgical resection is the only curative treatment. However, this procedure is linked to a significant risk of postoperative complications [3], and despite surgery, many patients relapse, leading to cancer-related death [4].
The pleiotropic effects of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, or statins, have gotten significant attention in oncological treatment in recent years. These drugs are widely used to treat dyslipidemia and to prevent cardiovascular disease [5]. Several preclinical and epidemiological studies have highlighted statins’ potential anti-tumor properties, including increased apoptosis [6, 7], reduced proliferation [8, 9], and reduced mortality [10, 11]. In addition, statins are believed to possess anti-inflammatory effects by inhibiting proinflammatory cytokines, such as IL-6, IL-8, and TNF-α [12]. These cytokines are typically released in response to surgical trauma. Thus, research has demonstrated an inverse correlation between the secretion of these cytokines and time to recovery [13, 14]. However, conflicting evidence about the protective effects of statins is evident in the literature, especially in cases of CRC [15, 16].
A Danish propensity score-matched cohort study that investigated statin exposure and short-term outcomes found no significant difference in 30-day survival between statin users and non-users in patients who underwent surgery for CRC [17]. Our hypothesis in this study was that statin exposure at any time 1 year before curative-intended surgery for CRC is associated with increased overall survival (OS) and 90-day survival. We aimed to investigate this in a nationwide propensity score-matched study.
Methods
This study, employing retrospective propensity score adjustments, utilized a Danish patient cohort that underwent elective curative-intended surgery for Union of International Cancer Control (UICC) stage I–III CRC between 2008 and 2020. Patients who underwent emergency surgical procedures were excluded. The research adheres to the guidelines outlined in “Strengthening the Reporting of Observational Studies in Epidemiology” (STROBE) [18].
Data sources
The data was sourced from the Danish Colorectal Cancer Group (DCCG), the Danish National Prescription Registry (NPR), the Danish Registry of Laboratory Results for Research (RLRR), and the Danish National Patient Registry (DNPR). The DCCG, established in 1994, constitutes a nationwide database encompassing patients aged 18 or above, possessing a Danish social security number, and diagnosed or surgically treated for primary CRC in a public Danish hospital from May 2001 onwards [19]. A recent validation of the database confirmed high completeness and quality [20]. Since 1994, comprehensive nationwide records of all prescribed medications have been registered in the NPR [21], while the RLRR has recorded individual biochemistry outcomes since 2008. These results originate from both private practitioners and public hospitals [22]. Lastly, established in 1977, the DNPR provides a comprehensive and longitudinal repository of administrative and clinical data at the national level. The database has recorded complete data encompassing treatments, diagnoses, and examinations across inpatient and outpatient clinics and emergency departments [23].
Data from the four databases were combined into a single Observational Medical Outcomes Partnership Common Data Model (OMOP CDM) through the utilization of open-source analytical tools created by the Observational Health Data Sciences and Informatics (OHDSI) community. The data extraction, transformation, and analysis process followed the principles of the OMOP [24].
Study population
The study included all adults aged 18 or older who underwent curative-intent surgical procedures for UICC stage I–III CRC from 2008 to 2020. The target cohort consisted of patients who had been prescribed statins, and these prescriptions were active or in use during the period spanning up to 365 days before the surgical procedure took place, whereas patients in the comparator cohort were not exposed to statins. In case of subjects that are in both the target and comparator cohorts, the subjects were excluded. No sample size calculations were computed.
Outcomes
The study’s primary outcome was to examine how preoperative statin exposure influences OS in patients having undergone curative intended surgery for UICC stage I–III CRC. OS was defined as the duration between the surgery to either death or the end of the 5-year follow-up period. The secondary outcomes were 90-day and disease-free survival. Disease-free survival analysis was performed in a cohort adhering to the criteria of the validated algorithm by Lash et al. [25]. In this analysis, time at risk is defined as 180 days following surgery until either recurrence, death, or end of follow-up. To assess the accuracy of the study design, five negative control outcomes were incorporated (Supplementary Table 1) [26].
Subgroup analyses
The first subgroup analysis investigated the association between statin exposure of more or less than 30 mg/day 1 year before surgery and the primary and secondary outcomes.
The second and third subgroup analyses investigated the association between statin exposure between 30 and 90 days preoperatively and the primary and secondary outcomes.
Finally, two subgroup analyses were made for either rectal or colon cancer.
Data security
This study obtained approval from the Danish Data Protection Agency under the registration number REG-102–2020. All data used in the research were anonymized and securely stored on the cloud-based platform Computerome 2.0, where all analyses were conducted.
Statistical analysis
Using the Cyclops package for R [27], propensity score (PS) models were constructed for the primary and subgroup analyses. To create balanced cohorts, we employed a 1:1 matching ratio based on these propensity scores, which gauged the likelihood of a patient in the comparator group receiving statins compared to receiving no treatment. These scores considered a comprehensive dataset, including patient observations, demographic information, drug exposure, prior medical procedures, and medical history, spanning from any time before surgery as well as 2 years preceding surgery. Covariates linked to the treatment exposure were excluded (see Supplementary Table 2). Additionally, quantitative biochemistry data contributed to the propensity score calculation by considering the following criteria:
-
Whether a specific analysis had been conducted for each patient
-
The quantitative value of the biochemistry data
-
Whether the biochemistry result fell within or outside the normal range
For missing records in the database, such as a missing diagnosis, we interpreted this as an absence of the diagnosis.
To match the patients 1:1, we employed a maximum caliper width of 0.2 standard deviation on the logit scale [28]. The evaluation of the PS model included a visual examination of Kernel density- and covariate balance scatter plots, along with the calculation of the standardized mean difference (SMD) for covariates. The predefined threshold for SMD difference was set at 0.1 in accordance with recommendations [29, 30]. Additionally, we conducted an unadjusted analysis in which the target and comparator cohorts were not matched.
To estimate the primary outcome, we utilized the Cox proportional hazards model, while a logistic regression model was employed for estimating the secondary outcomes. The results are presented as hazard ratios (HR) for the primary outcome analysis and odds ratios (OR) for the secondary outcome analyses, accompanied by 95% confidence intervals (CI). The proportional hazards assumption was evaluated to ascertain the constancy of hazard ratios over time with log–log survival plots and examination of Schoenfeld residuals. Cohorts were created using the open-source tool ATLAS, while analyses were carried through in R (version 4.2.0).
Results
Six thousand four hundred fifty-one individuals who underwent elective surgery for CRC stage I–III between 2008 and 2020 with exposure to statins 365 days before the operation could be identified as the target group. The comparator cohort, consisting of patients not exposed to statins before surgery, comprised 20,477 individuals. After propensity score matching, both cohorts were reduced to 3560 patients each, resulting in a final analysis encompassing 7120 patients. The median follow-up time was 5.0 years (interquartile range [IQR] 2.6–5.0 years).
Patient characteristics
On average and before propensity score matching, the patient group exposed to statins is older than the non-exposed group (SMD 0.12) and contains more males than females. Other notable differences in the exposed group are the higher percentage of patients in American Society of Anesthesiologists (ASA) group 3 (32.5% compared to 15.0%) as well as generally higher scores in the Charlson comorbidity index (see Table 1). These characteristics, as observed in our study, align with patterns identified in the general population of patients with colorectal cancer, as reported in the Danish Colorectal Cancer Group’s latest report from 2022 [31].
Propensity score matching
Figure 1 shows the density plots of the propensity scores before and after matching.
The scatterplot illustrating the SMD before and after matching (Supplementary Fig. 1) indicates that 0.002% of the covariates (12 out of 61,231) exhibited SMD values below − 0.1 or above 0.1 following matching. Notably, the covariates showing the most substantial deviations from the threshold included the use of beta-blocking agents and thiazides within the 2 years preceding surgery, as well as at any time before the surgery.
Overall survival
The unadjusted analysis that was performed of the groups before matching showed a statistically significant difference in OS between the patients exposed to statins 365 days before surgery versus the unexposed group (HR 1.06, 95% CI 1.01–1.12).
In the main analysis, the Cox PH model showed no statistically significant difference in OS between patients with statin exposure 365 days before surgery and those without statin exposure (HR 0.93, 95% CI 0.85–1.02) after PS matching (Fig. 2).
The log-log representation of survival trends and the evaluation of Schoenfeld residuals revealed no notable breaches of the assumption of proportional hazards.
The subgroup analysis examining a 90-day exposure to statins before surgery found the target group to have a significantly higher OS than the control group (HR 0.85, 95% CI 0.77–0.93). The subgroup analysis examining a 30-day exposure of statins before surgery (HR 0.89, 95% CI 0.78–1.01) as well as a statin dose of > 30 mg/day as opposed to ≤ 30 mg/day, 365 days preoperatively (HR 0.96, 95% CI 0.85–1.09), did not find a significant association with OS. The subanalysis investigating an association in the rectum cancer group found no significant association (HR 0.87, 95% CI 0.74–1.01). However, the colon cancer subgroup found the cohort exposed to statins to have a significantly higher OS (HR 0.85, 95% CI 0.76–0.95) (see Fig. 3).
Ninety-day survival
The logistic regression model showed no statistically significant difference in 90-day survival between patients with statin exposure 365 days before surgery versus no statin exposure before surgery (OR 0.91, 95% CI 0.76–1.10). The subgroup analyses examining a 90- and 30-day exposure of statins before surgery did not find a significant association with 90-day survival (OR 0.90, 95% CI 0.75–1.08, and OR 1.10, 95% CI 0.84–1.43, respectively). Furthermore, there was no association in the subanalysis of > 30 mg statin/day 365 days preoperatively as opposed to ≤ 30 mg/day with 90-day survival (OR 0.92, 95% CI 0.71–1.19). The subanalyses looking into colon or rectal tumor only did not show any significant association (OR 0.88, 95% CI 0.71–1.09, and OR 1.03, 95% CI 0.73–1.46, respectively) (see Fig. 4).
Disease-free survival
For the main analysis, the Cox PH model showed no statistically significant difference in DFS between patients with statin exposure 365 days before surgery and those without statin exposure (HR 0.93, 95% CI 0.84–1.03) after PS matching.
Discussion
This study investigated the association between statin exposure and OS in patients undergoing elective colorectal cancer surgery in 2008–2020. The primary analysis of this study found no significant association between statin exposure at any time 365 days before surgery and improved OS. However, a subgroup analysis revealed a significant association when the exposure period of statins was 90 days before surgery. While the unadjusted analysis indicates a higher risk of death for patients exposed to statins, the propensity score-matched analysis shows a statistically significant improvement in OS for patients exposed to statins, accounting for potential confounding variables. There was no association with short-term survival.
The study’s findings add to the notion that statins may improve OS. While our study does not provide conclusive evidence to recommend the use of statins within 90 days prior to surgery, the observed positive association with overall survival suggests a potential avenue for further exploration, for example, through translational research. Investigating specific signaling pathways, immune modulation, and relevant biological processes could help uncover the mechanisms through which statins influence the disease. Additionally, studying changes in immune cell populations, cytokine profiles, and response dynamics within the tumor could provide insights into how statins contribute to a more favorable environment for overall survival. This could pave the way for a more comprehensive understanding and potentially enhance the clinical relevance of statins in the context of colorectal cancer management. However, the protective effects of statins in patients with CRC are still debated, and results are conflicting. While Poynter et al. found a 47% decrease in the relative risk (RR) of the development of CRC when exposed to statins for a period of 5 years [11], a meta-analysis that included 18 studies reviewed the preventive effects of statins in patients with CRC and suggested that there is no substantial evidence to support this claim. Nevertheless, a slight reduction of risk cannot be ruled out [15]. A different meta-study reviewed both the preventive role of statins in CRC patients and its role in adjuvant therapy, concluding that statins may decrease the invasiveness or metastatic properties of CRC as well as sensitizing the tumor to chemotherapeutic agents. However, further research is needed to assess this hypothesis [16]. A Swedish retrospective study [32] reported a statistically significant lower 90-day survival in patients with colon cancer, whereas our study found no significant association between statin exposure and 90-day survival in this same subgroup. Our study used the propensity score matching method, while the Swedish study chose covariates for matching, including sex, age, BMI, cancer stage, and surgical details. Both studies observed that statin users tend to be older and have more comorbidities. Notably, the Swedish study had a larger sample size (6494 patients) than ours (3560 patients). These differences in study design and sample size could contribute to the divergent results and highlight the need for further investigation in the context of colon cancer treatment and statin therapy. In general, study designs and patient characteristics in all studies above were heterogeneous, thus increasing variability in study outcomes. Another aspect that could explain the conflicting evidence regarding the protective effect of statins in patients with CRC is patient compliance as well as the COVID-19 pandemic.
Studies suggest that statins may have protective effects against severe COVID-19 outcomes by mitigating inflammation, highlighting their multifaceted potential in the context of both colorectal cancer and infectious diseases like COVID-19 [33, 34].
This study’s strengths lie in its use of nationwide population-based databases within the OMOP-CDM framework, enabling detailed propensity score calculation. Matching based on these scores minimizes confounding, approximating the randomized controlled trial (RCT) gold standard [29]. National Danish registry data collection is uniform and comprehensive, reducing selection and attrition bias.
Adopting OHDSI’s open-source tools establishes a standardized framework for observational health research, enhancing reproducibility, transparency, and data consistency.
However, unaccounted covariates in the CDM, such as over-the-counter medications, behavior, and lifestyle, can introduce residual confounding. Further potential issues include missing data, misregistration, and the inability to assess statin compliance in this model. While our study did not explicitly account for socioeconomic factors, it is essential to contextualize our findings within the broader landscape highlighted by previous research. Notably, low socioeconomic position (SEP), especially low income, consistently associates with statin non-adherence, as evidenced by Danish and Finnish studies [35, 36]—both countries with universal healthcare—conducted on data from 1995 to 2004. These investigations explored the correlation between SEP and statin utilization, revealing a socioeconomic gradient in statin use among men. Intriguingly, no such clear association was observed among women, suggesting potential gender-specific variations in the influence of socioeconomic factors on medication use. Although these studies utilize older data, their findings emphasize the enduring relevance of socioeconomic status as a potential confounder in studies evaluating statin effectiveness. The identified socioeconomic gradient among men underscores the necessity of considering SEP when interpreting and generalizing results from studies assessing the impact of statins on health outcomes.
In conclusion, this study found no significant association between statin exposure within 365 days before surgery and improved OS in patients with CRC. A subgroup analysis investigating a 90-day exposure before surgery found a significant association, suggesting that statins may have a potential role in the survival of patients with CRC. Further research is needed to understand statins’ effects on CRC patients better— conducting translational analyses to delve into molecular mechanisms, immune modulation, and patient-specific factors could thus hold the potential to offer valuable insights, laying the groundwork for future clinical applicability.
Data availability
The sharing of source data is prohibited under Danish legislation, as it includes sensitive personal information.
References
Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660
Xi Y, Xu P (2021) Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol 14:101174. https://doi.org/10.1016/j.tranon.2021.101174
Pearse RM, Clavien PA, Demartines N et al (2016) Global patient outcomes after elective surgery: prospective cohort study in 27 low-, middle- and high-income countries. Br J Anaesth 117:601–609. https://doi.org/10.1093/bja/aew316
Tohme S, Simmons RL, Tsung A (2017) Surgery for cancer: a trigger for metastases. Cancer Res 77:1548–1552. https://doi.org/10.1158/0008-5472.CAN-16-1536
Taylor F, Huffman MD, Macedo AF et al (2013) Statins for the primary prevention of cardiovascular disease. Cochrane database Syst Rev 2013:CD004816. https://doi.org/10.1002/14651858.CD004816.pub5
Kato S, Smalley S, Sadarangani A et al (2010) Lipophilic but not hydrophilic statins selectively induce cell death in gynaecological cancers expressing high levels of HMGCoA reductase. J Cell Mol Med 14:1180–1193. https://doi.org/10.1111/j.1582-4934.2009.00771.x
Zhu Y, Casey PJ, Kumar AP, Pervaiz S (2013) Deciphering the signaling networks underlying simvastatin-induced apoptosis in human cancer cells: evidence for non-canonical activation of RhoA and Rac1 GTPases. Cell Death Dis 4:e568–e568. https://doi.org/10.1038/cddis.2013.103
Björkhem-Bergman L, Acimovic J, Torndal UB et al (2010) Lovastatin prevents carcinogenesis in a rat model for liver cancer. Effects of ubiquinone supplementation. Anticancer Res 30:1105–1112
Kubatka P, Kajo K, Zihlavnikova K et al (2012) Immunohistochemical and histomorphological analysis of rat mammary tumors after simvastatin treatment. Neoplasma 59:516–523. https://doi.org/10.4149/neo_2012_066
Nielsen SF, Nordestgaard BG, Bojesen SE (2012) Statin use and reduced cancer-related mortality. N Engl J Med 367:1792–1802. https://doi.org/10.1056/nejmoa1201735
Poynter JN, Gruber SB, Higgins PDR et al (2005) Statins and the risk of colorectal cancer. N Engl J Med 352:2184–2192. https://doi.org/10.1056/nejmoa043792
Loppnow H, Zhang L, Buerke M et al (2011) Statins potently reduce the cytokine-mediated IL-6 release in SMC/MNC cocultures. J Cell Mol Med 15:994–1004. https://doi.org/10.1111/j.1582-4934.2010.01036.x
Schurr JW, Wu W, Smith-Hannah A et al (2016) Incidence of sepsis and mortality with prior exposure of HMG-COA reductase inhibitors in a surgical intensive care population. Shock 45:10–15. https://doi.org/10.1097/SHK.0000000000000484
Singh PP, Srinivasa S, Bambarawana S et al (2012) Perioperative use of statins in elective colectomy. Dis Colon Rectum 55:205–210. https://doi.org/10.1097/DCR.0b013e31823d2db6
Bonovas S, Filioussi K, Flordellis CS, Sitaras NM (2007) Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million patients. J Clin Oncol 25:3462–3468. https://doi.org/10.1200/JCO.2007.10.8936
Bardou M, Barkun A, Martel M (2010) Effect of statin therapy on colorectal cancer. Gut 59:1572–1585. https://doi.org/10.1136/gut.2009.190900
Fransgaard T, Thygesen LC, Gögenur I (2018) Statin use is not associated with improved 30-day survival in patients undergoing surgery for colorectal cancer. Int J Colorectal Dis 33:199–207. https://doi.org/10.1007/s00384-017-2947-9
von Elm E, Altman DG, Egger M et al (2014) The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. Int J Surg 12:1495–1499. https://doi.org/10.1016/j.ijsu.2014.07.013
Ingeholm P, Gögenur I, Iversen LH (2016) Danish Colorectal Cancer Group Database. Clin Epidemiol 8:465–468
Klein MF, Gögenur I, Ingeholm P et al (2020) Validation of the Danish colorectal cancer group (DCCG.dk) database – on behalf of the Danish colorectal cancer group. Color Dis 22:2057–2067. https://doi.org/10.1111/codi.15352
Kildemoes HW, Sørensen HT, Hallas J (2011) The danish national prescription registry. Scand J Public Health 39:38–41. https://doi.org/10.1177/1403494810394717
Arendt JFH, Hansen AT, Ladefoged SA et al (2020) Existing data sources in clinical epidemiology: laboratory information system databases in Denmark. Clin Epidemiol 12:469–475. https://doi.org/10.2147/CLEP.S245060
Sandegaard JL, Ehrenstein V, Pedersen L (2015) The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol 7:449–490
Hripcsak G, Duke JD, Shah NH et al (2015) Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform 216:574–578. https://doi.org/10.3233/978-1-61499-564-7-574
Lash TL, Riis AH, Ostenfeld EB et al (2015) A validated algorithm to ascertain colorectal cancer recurrence using registry resources in Denmark. Int J Cancer 136:2210–2215. https://doi.org/10.1002/ijc.29267
Lipsitch M, Tchetgen Tchetgen E, Cohen T (2010) Negative controls: a tool for detecting confounding and bias in observational studies. Epidemiology 21:383–388. https://doi.org/10.1097/EDE.0b013e3181d61eeb
Suchard MA, Schuemie MJ, Shaddox TR, Tian Y, Yang J, Kawaguchi ES (2023) Cyclic coordinate descent for logistic, Poisson and survival analysis (Cyclops). https://ohdsi.github.io/Cyclops/. Accessed 6 Sep 2023
Austin PC (2011) Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat 10:150–161. https://doi.org/10.1002/pst.433
Austin PC (2011) An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 46:399–424. https://doi.org/10.1080/00273171.2011.568786
Zhang Z, Kim HJ, Lonjon G, Zhu Y (2019) Balance diagnostics after propensity score matching. Ann Transl Med 7:16–16. https://doi.org/10.21037/atm.2018.12.10
Danish Colorectal Cancer Group (2023) Landsdækkende database for kræft i tyk- og endetarm. National årsrapport 2022. https://dccg.dk/wp-content/uploads/2023/10/4681_dccg-aarsrapport-2022_offentliggjort-version.pdf
Pourlotfi A, Ahl Hulme R, Bass GA et al (2022) Statin therapy is associated with decreased 90-day postoperative mortality after colon cancer surgery. Dis Colon Rectum 65:559–565. https://doi.org/10.1097/DCR.0000000000001933
Santosa A, Franzén S, Nåtman J et al (2022) Protective effects of statins on COVID-19 risk, severity and fatal outcome: a nationwide Swedish cohort study. Sci Rep 12:12047. https://doi.org/10.1038/s41598-022-16357-2
Kouhpeikar H, Khosaravizade Tabasi H, Khazir Z et al (2022) Statin use in COVID-19 hospitalized patients and outcomes: a retrospective study. Front Cardiovasc Med. https://doi.org/10.3389/fcvm.2022.820260
Aarnio E, Martikainen J, Winn AN et al (2016) Socioeconomic inequalities in statin adherence under universal coverage: does sex matter? Circ Cardiovasc Qual Outcomes 9:704–713. https://doi.org/10.1161/CIRCOUTCOMES.116.002728
Thomsen RW, Johnsen SP, Olesen AV et al (2005) Socioeconomic gradient in use of statins among Danish patients: population-based cross-sectional study. Br J Clin Pharmacol 60:534–542. https://doi.org/10.1111/j.1365-2125.2005.02494.x
Acknowledgements
The authors thank Computerome at the Technical University of Denmark as well as OHDSI for their contributions and for providing access to the open-source analytical tool ATLAS. Acknowledgements are also conveyed to the Danish Colorectal Cancer Group for supplying crucial data for the study.
Funding
Open access funding provided by Zealand Region This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) (grant agreement #806968). Further, the Novo Nordisk Foundation has granted funding (Grant number NNF21OC0069821). Finally, the Region Zealand and the Danish Ministry of Higher Education and Science granted funding for the project.
Author information
Authors and Affiliations
Contributions
Conceptualization and methodology, Lea Löffler, Mikail Gögenur and Ismail Gögenur; Formal analysis, Lea Löffler and Mikail Gögenur; writing – original draft, Lea Löffler; writing – review and editing, Lea Löffler, Ismail Gögenur, Mikail Gögenur. The corresponding author attests that all listed authors meet required criteria and that no others have been omitted.
Corresponding author
Ethics declarations
Ethics approval and consent to participate
Approval for this study was granted by the Danish Data Protection Agency under the approval number REG-102–2020. The study’s retrospective design and the de-identification of patient data meant that ethics approval or written consent for participation in the research was not necessary.
Permission to reproduce material from other sources
Not applicable.
Clinical trial registration
Not applicable.
Disclaimer
Funding parties were not involved in the design, analyses, or writing of this study.
Competing interests
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Löffler, L., Gögenur, I. & Gögenur, M. Correlations between preoperative statin treatment with short- and long-term survival following colorectal cancer surgery: a propensity score-matched national cohort study. Int J Colorectal Dis 39, 60 (2024). https://doi.org/10.1007/s00384-024-04631-w
Accepted:
Published:
DOI: https://doi.org/10.1007/s00384-024-04631-w